Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06835504

Morphine or Ketamine for Analgesia

Efficacy of Intravenous Sub-Dissociative Ketamine Versus Intravenous Morphine in Children With Acute Pain

Status
Not Yet Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
1,010 (estimated)
Sponsor
Columbia University · Academic / Other
Sex
All
Age
6 Years – 17 Years
Healthy volunteers
Not accepted

Summary

Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative for treating acute pain in children because of its more favorable side effect profile and potential long-term benefits related to pain-related function, analgesic use/misuse, and mental and behavioral health outcomes.

Detailed description

Aim 1: To determine if IV sub-dissociative ketamine is non-inferior to IV morphine for decreasing pain intensity in children presenting to an ED with acute pain. The investigators hypothesize that IV sub-dissociative ketamine is non-inferior to IV morphine for decreasing pain intensity in children with acute abdominal pain or an extremity fracture. Aim 2: To compare the rate of acute (\<2 hours) adverse events, including cardiopulmonary adverse events, associated with IV sub-dissociative ketamine and IV morphine. The investigators hypothesize that there is a smaller proportion of cardiopulmonary adverse events associated with IV sub-dissociative ketamine compared to IV morphine. Aim 3: To determine the relationship between ketamine and long-term sequelae of acute pain. The investigators hypothesize that children who receive ketamine will have better levels of pain-related function during the first week following ED presentation and will have greater odds of experiencing more favorable post-traumatic stress, anxiety and depression outcomes 1-6 months after ED presentation compared to children who received IV morphine.

Conditions

Interventions

TypeNameDescription
DRUGKetamine hydrochlorideSub-dissociative ketamine, IV
DRUGMorphine sulphateMorphine, IV

Timeline

Start date
2026-05-01
Primary completion
2029-04-30
Completion
2029-10-31
First posted
2025-02-19
Last updated
2026-01-26

Locations

8 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06835504. Inclusion in this directory is not an endorsement.